Aquestive Therapeutics Inc. (AQST)
4.05
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K Aquestive Therapeutics, For: Oct 15
October 19, 2026 4:05 PM - SEC Filing
Form 4 Aquestive Therapeutics, For: Oct 15 Filed by: Barber Daniel
October 16, 2026 2:17 PM - SEC Filing
Form 3 Aquestive Therapeutics, For: Oct 15 Filed by: Daly Richard J
October 16, 2026 1:58 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST)
October 16, 2026 8:07 AM - StreetInsider
Form 8-K Aquestive Therapeutics, For: Oct 15
October 15, 2026 7:21 AM - SEC Filing
FDA accepts Aquestive's Anaphylm NDA resubmission with March 2027 review date
October 15, 2026 7:00 AM - StreetInsider
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
October 15, 2026 7:00 AM - StreetInsider
Form 8-K Aquestive Therapeutics, For: Oct 13
October 14, 2026 7:21 AM - SEC Filing
Eton and Aquestive strike U.S. deal for diazepam buccal film
October 14, 2026 6:51 AM - StreetInsider
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
October 14, 2026 6:50 AM - StreetInsider
Form SCHEDULE 13G Aquestive Therapeutics, Filed by: Bass Edward P
October 7, 2026 3:47 PM - SEC Filing
Form SCHEDULE 13G/A Aquestive Therapeutics, Filed by: BRATTON DOUGLAS K
October 7, 2026 2:14 PM - SEC Filing
Form 8-K Aquestive Therapeutics, For: Sep 29
September 29, 2026 7:22 AM - SEC Filing
Aquestive Therapeutics names Richard Daly to its board of directors
September 29, 2026 7:02 AM - StreetInsider
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
September 29, 2026 7:00 AM - StreetInsider
Form 8-K Aquestive Therapeutics, For: Sep 23
September 25, 2026 7:59 AM - SEC Filing
Form 8-K Aquestive Therapeutics, For: Sep 14
September 17, 2026 7:03 AM - SEC Filing
Aquestive resubmits NDA to FDA for Anaphylm sublingual film
September 17, 2026 7:00 AM - StreetInsider
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
September 17, 2026 7:00 AM - StreetInsider
Form 4 Aquestive Therapeutics, For: Sep 15 Filed by: Barber Daniel
September 16, 2026 2:01 PM - SEC Filing
Form 144 Aquestive Therapeutics, Filed by: Barber Daniel
September 15, 2026 4:49 PM - SEC Filing
Form 4 Aquestive Therapeutics, For: Sep 09 Filed by: Korczynski Sherry
September 11, 2026 11:08 AM - SEC Filing
Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST)
September 10, 2026 9:31 AM - StreetInsider
Form 4 Aquestive Therapeutics, For: Sep 09 Filed by: Boyd Peter E.
September 10, 2026 9:22 AM - SEC Filing
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
September 1, 2026 7:00 AM - StreetInsider
Form 4 Aquestive Therapeutics, For: Aug 17 Filed by: Barber Daniel
August 18, 2026 4:13 PM - SEC Filing
Form 4 Aquestive Therapeutics, For: Aug 14 Filed by: Korczynski Sherry
August 17, 2026 5:34 PM - SEC Filing
Form 144 Aquestive Therapeutics, Filed by: Barber Daniel
August 17, 2026 4:35 PM - SEC Filing
Form 10-Q Aquestive Therapeutics, For: Jun 30
August 11, 2026 4:12 PM - SEC Filing
Form 8-K Aquestive Therapeutics, For: Aug 11
August 11, 2026 4:07 PM - SEC Filing
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026 4:01 PM - Globe NewsWire
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026 4:01 PM - StreetInsider
Form 8-K Aquestive Therapeutics, For: Aug 10
August 10, 2026 7:06 AM - SEC Filing
Aquestive reports study results for Anaphylm ahead of NDA resubmission
August 10, 2026 7:02 AM - StreetInsider
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
August 10, 2026 7:00 AM - StreetInsider
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
July 29, 2026 7:00 AM - StreetInsider
Form SCHEDULE 13G/A Aquestive Therapeutics, Filed by: BlackRock, Inc.
July 27, 2026 4:26 PM - SEC Filing
Full Article List
